The Journal of Cancer Research最新文献

{"title":"Delayed Immune-Related Erythrodermia in a Squamous NSCLC Patient Treated with Nivolumab: A Case Report","authors":"D. Iacono, G. Osman, Romano Mcp, S. Ricciardi, S. Greco, M. Signora, A. Lombardi, G. Pallone, R. Pacifici, M. Migliorino","doi":"10.35248/2684-1266.18.4.113","DOIUrl":"https://doi.org/10.35248/2684-1266.18.4.113","url":null,"abstract":"Immunotherapy has been changing the scenario of the treatment of non-small cell lung cancer (NSCLC) and is leading to a dramatic improvement in the clinical outcome of patients suffering from this disease. Immunotherapy has a specific toxicity profile and many oncologists are facing a new challenge in the form of clinical management of immune-related adverse events (irAEs). Even though most irAEs remain mild in intensity, around 10% of patients treated with anti-PD1/anti-PDL1 drugs will develop severe, sometimes life-threatening, dysimmune toxicities. Skin toxicity is one of the most common irAEs. The irAEs related to skin toxicity can have many different presentations, which includes maculopapular or papulopustular rash, Sweet’s syndrome, follicular or urticarial dermatitis. It typically occurs within 6 weeks from the beginning of the treatment but, due to the mechanism of action of immunotherapic drugs, delayed toxicities are reported. We present a case study of delayed grade 4 skin toxicity in a 75-year-old male patient with stage IV squamous NSCLC treated with Nivolumab.","PeriodicalId":22619,"journal":{"name":"The Journal of Cancer Research","volume":"23 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89836587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"外泌体生物学特性及其在肝癌中的作用研究 Biological Characteristics of Exosomes and Their Role in Hepatocellular Carcinoma","authors":"张腾飞, 黄修燕","doi":"10.12677/WJCR.2018.81003","DOIUrl":"https://doi.org/10.12677/WJCR.2018.81003","url":null,"abstract":"肝细胞癌(HCC)发生发展的分子机制尚未完全清楚，可能涉及病毒致癌作用、癌基因和抑癌基因失活、癌细胞凋亡等。外泌体能介导细胞间物质传递和信息交流，在多种癌症发生发展中起着重要作用。本文旨在总结外泌体生物学特性及其在肝癌发生发展、诊断和治疗中的作用。 The mechanism of hepatocellular carcinoma (HCC) development is not yet fully understood, which may be related to the carcinogenesis of the virus, the inactivation of oncogenes and tumor sup-pressor genes, cancer cell apoptosis. Exosomes, which can mediate the material transfer between cells and the exchange of information, play significant roles in the occurrence and development of a variety of cancers. This article aims to summarize the biological characteristics of exosomes and their roles in the development, diagnosis and treatment of HCC.","PeriodicalId":22619,"journal":{"name":"The Journal of Cancer Research","volume":"43 1","pages":"12-17"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84686585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Evaluation of Palliative Radiotherapy with Chemotherapy vs.Palliative Radiotherapy Alone in Locally Advanced Head and Neck Cancer","authors":"Manas Dubey, R. Dhankhar, V. Kaushal, K. Dahiya, O. Parkash, A. Dhull, R. Atri","doi":"10.35248/2684-1266.16.4.116","DOIUrl":"https://doi.org/10.35248/2684-1266.16.4.116","url":null,"abstract":"Background: The aim of the study was to evaluate and compare the efficacy, tolerability and toxicity of two palliative radiotherapy (RT) schedules in locally advanced head and neck carcinoma (LAHNC), i.e., Quad Shot schedule with chemotherapy and Quad Shot schedule alone. Methods: The patients were randomly divided into two groups of 30 each. Group I patients were planned for 14.8 Gy in 4 fractions over 2 days every 3 weeks for three cycles. All these patients also received paclitaxel 60 mg/m2 intravenous. Group II patients received 14.8 Gy in 4 fractions over 2 days every 3 weeks for three cycles alone. All these patients in Group I and II received total radiation dose of 44.4 Gy. Results: At the end of treatment, complete tumor response (CR) in Group I was better than Group II (40% vs. 36.7%). Disease status (tumor+node) at the end of treatment in terms of complete response was 36.7% vs. 0% (11/30 and 0/30) in Group I and II. Disease status at 6 months of follow up was noted as follows: complete tumor response in Group I and II was 23.3% (7/30) vs. 10% (3/30) (p=0.012). Complete nodal response was 35.7% (10/28) in Group I and 6.67% (02/30) in Group II (p= 0.538). Overall, no evidence of disease was observed in 16.7% (5/30) in Group I and 3.3% (1/30) in Group II respectively (p<0.001). Conclusion: This palliative schedule has been shown to provide good tumor response and palliation of symptoms. The toxicity profile remains low with the addition of paclitaxel. Further investigation is warranted in a larger trial. Palliation of symptoms resulted in improved quality of life for these group of patients","PeriodicalId":22619,"journal":{"name":"The Journal of Cancer Research","volume":"4 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81491368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curcumin Co-Treatment Sensitizes Multi-Drug Resistant Ht29 Colon Cancer Cell Line","authors":"Abdul Rouf War","doi":"10.35248/2684-1266.16.4.117","DOIUrl":"https://doi.org/10.35248/2684-1266.16.4.117","url":null,"abstract":"Colorectal cancer has been confirmed to be the third most dreadful cancer across the world. The latest reports show that the colorectal cancer is increasing in India at a high rate due to food habits, particularly consuming the foods with high fat content. Chemotherapy has been considered as a potential treatment in the control of a wide range of cancers recently, such as gastrointestinal cancers and so on. The scientists are looking to come up with new drugs to treat cancer by regulating the carcinogenesis with minimal toxicity. Curcumin is a phytochemical extracted from turmeric. It is highly effective product of the rhizomes of Curcuma longa L. (Zingiberaceae). It is also considered as a valuable drug for chemotherapeutic treatments in cancer. In case of animal studies, it has been clearly mentioned that curcumin controls carcinogenesis in various other organs as well as colon. Curcumin exhibits the capability to act as anti-mutagenic, anti-inflammatory drug as well. It has also been confirmed that the P-gp expression regulation is carried out by curcumin by inhibiting the COX-2 expression. Also, it has been clearly stated that curcumin down-regulates NF-kB pathway in various cell lines like Colo 205 colon cancer cell line etc. Multi Drug Resistance (MDR) plays a key role in case of the cancer cells to exhibit the resistance against the cytotoxicity of various chemotherapeutic drugs. This type of characteristics in cancer cells is developed due to low levels of the chemotherapeutic drug accumulated inside the cells during repeated exposure to the drug, showing the over-expression of P-glycoprotein (MDR-1). P-glycoprotein, a transporter protein, allows the cells to expel the wide range of chemotherapeutic drugs. The latest reports show that COX-2 expression and P-gp expression possess strong correlation with each other. In this research study, we generated the Multi-Drug Resistant HT29 Human colon cancer cells by treating the cells with increasing concentrations of a chemotherapeutic drug namely Doxorubicin Hydrochloride (DOX) and further we estimated the intracellular drug concentration in treated live as well as dead cells with the help of Doxorubicin Accumulation Assay. Also, the cell morphology change was studied in HT29 cells after every 24 hours of the DOX treatment separately as well as curcumin co-treatment (DOX+Curcumin). The curcumin co-treatment was carried out to observe the effect of curcumin on multi-drug resistant HT29 colon cancer cells and further study can be extended to investigate the various inflammatory genes controlled by NFkB at mRNA and protein level as well as the levels of cytokines which may get down-regulated by treatment. This study will help to completely understand the mechanism of reducing the effect of Multidrug Resistance (a unique property of cancer) by curcumin in case of colon cancer.","PeriodicalId":22619,"journal":{"name":"The Journal of Cancer Research","volume":"1 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83711636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"临朐县上消化道癌早诊早治项目工作十年进展 Review on Mass Screening and GC Early Detection in Linqu, Shandong (2008-2016)","authors":"王建玺, 刘卫东, 刘堃, 李毅, 吴齐, 吴秀贞, 刘艳刚, 朱勤, 马建, 张兰福, 张联","doi":"10.12677/WJCR.2018.81002","DOIUrl":"https://doi.org/10.12677/WJCR.2018.81002","url":null,"abstract":"2008~2017年临朐县对当地农村居民进行了上消化道癌(胃癌、食管癌)早诊早治筛查，十年来，总计筛查22,725人，发现胃癌、食管癌323例，其中早癌271例(83.9%)。2012年以后，注重人群选择、采用新的胃镜精查技术、加强内镜、病理专业技术人员的培训，使内窥镜诊断技术及病理诊断技术得到了明显提升，检出率从0.66% (0.46~1.11)逐步提高到2.17% (1.26~2.17)，最高检出率达2.17%，明显增多上消化道癌病人的发现。选择合适人群、加强项目管理、医护人员培训和内镜、病理检查技术的提高是提升上消化道癌早诊早治项目水平的关键，可使上消化道癌高发地区广大居民受益。 Objectives: To summarizes the newest progression of mass screening and gastric cancer (GC) early detection in a high-risk population in 2008-2017. Methods: Since 2008, a project of mass screening and GC early detection was conducted in Linqu. After 2012, an endoscopic examination technique was used, which was more detailed than traditional examination, with additional NBI. The time for each endoscopic examination was controlled between 20 - 30 mins and at least 48 images were saved for further comprehensive diagnosis. Results: 323 cases of GC patients were diagnosed among 22,725 subjects in 2008-2017, in which, 271 of early cancers (83.9%). The positive rate of GC detection was increased from 0.66% to 2.17% after 2012. Almost of GC patients were received the medical treatment and alive with a high quality. Conclusions: A project of mass screening and GC early detection has been carried out very well and effectively in Linqu.","PeriodicalId":22619,"journal":{"name":"The Journal of Cancer Research","volume":"5 1","pages":"6-11"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75042317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sertoli-Leydig Cell Tumor of the Ovary in a Postmenopausal Woman","authors":"Debora Chantada de la Fuente, María Angeles Peteiro Cancelo, Laura Juaneda-Magdalena Benavides, Lara Alberta Lista","doi":"10.35248/2684-1266.18.4.111","DOIUrl":"https://doi.org/10.35248/2684-1266.18.4.111","url":null,"abstract":"Sertoli-Leydig cell tumor of the ovary represents less than 0.5% of all ovary neoplasms. It is a tumor that affects predominantly young woman, who most of the times associate signs of virilization. It has recently been associated with mutations in DICER1. In this report, we describe a case of Sertoli-Leydig cell tumor in an asymptomatic 61- year-oldwoman who underwent a laparoscopic bilateral anexectomy for a heterogenous cystic lesion found in her left ovary. The microscopic examination of the lesion, showed a solid-cystic tumoral proliferation in the region identified as ovarian hilum, formed by two distinct and intermixed cell populations (Leydig cells and Sertoli cells). The prognosis of this kind of tumor is usually good, unless it shows poor differentiation and/or heterologous elements or retiforme pattern. So, the recommended treatment of these tumors, is a conservative approach. In our case, the anexectomy was performed by expressed desire of the patient.","PeriodicalId":22619,"journal":{"name":"The Journal of Cancer Research","volume":"109 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75209329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"58例低级别脑胶质瘤术后放化疗疗效及预后相关因素分析 Analysis of the Curative Effect and Prognosis of 58 Cases of Low-Grade Gliomas Treated by Postoperative Chemo-Radiotherapy","authors":"Mang Zhang, Wei-li Wu, Feng Jin, Jinhua Long, Yuanyuan Li, Xiuling Luo, X. Gong, Xiaoxiao Chen, Chunli Yang, Hongtao Zhao","doi":"10.12677/WJCR.2018.81009","DOIUrl":"https://doi.org/10.12677/WJCR.2018.81009","url":null,"abstract":"目的：探讨影响低级别胶质瘤长期生存的相关因素。方法：回顾分析2008年8月至2016年5月贵州医科大学附属肿瘤医院头颈肿瘤科收治的有完整病案及随访资料的58例低级别脑胶质瘤术后患者，单纯放疗14例，放疗联合替莫唑胺化疗44例。应用Kaplan-Meier法计算总生存率，Cox法多因素预后分析。结果：随访率为100.0%，随访时间满3、5年的病例数分别为50、29例。全组肿瘤患者5年总生存率为80.9%，中位生存时间为53.0个月。多因素分析显示诊断时年龄 ≤ 40岁、首发症状为癫痫、肿瘤病理亚型为少突星形、肿瘤全切除者有较好的预后。结论：诊断年龄 ≤ 40岁、首发症状为癫痫发作、肿瘤全切除者是影响低级别胶质瘤患者长期生存的有益因素。对于有高危因素或未达肿瘤全切除患者，建议术后4周内尽早开始放疗。是否联合替莫唑胺化疗仍需要扩大病例数及延长随访时间进一步研究。 Objective: To investigate the factors influencing the long-term survival of low-grade gliomas. Me-thods: We reviewed and analyzed 58 patients of low-grade glioma patients after surgery, who was admitted to Guizhou Medical University Affiliated Cancer Hospital head and neck cancer from Au-gust 2008 to May 2016. Among the patients, 14 only received radiotherapy, 44 cases received ra-diotherapy combined with temozolomide chemotherapy. Kaplan-Meier method was used to cal-culate the overall survival rate and the Cox regression model was used for multivariate prognostic analysis. Results: The follow-up rate was 100.0%, 50 patients were followed up for at least 3 year, and 29 for at least 5 years. The overall 5-year overall survival rate was 80.9%, the median survival time was 53.0 months. Multivariate analysis showed that the diagnosis of age ≤ 40 years, the first symptom of epilepsy, tumor pathologic subtypes was the less sudden star, total tumor resection has a better prognosis. Conclusions: Diagnosis of age ≤ 40 years, the first symptom of seizures, total tumor resection is the favorable prognostic factor for the long-tem survival in patients with low-grade glioma. Tumor pathological types have some reference value for the prognosis. For pa-tients with risk factors or less than complete resection of the tumor, it is recommended to start radiotherapy within 4 weeks after surgery as soon as possible. Whether combined with temozo-lomide chemotherapy needs to expand the number of cases and extend the follow-up time to study validation.","PeriodicalId":22619,"journal":{"name":"The Journal of Cancer Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91228991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"雌二醇E2通过调控PEDF表达促进乳腺癌增殖作用研究The Effect of Estradiol E2 on the Proliferation of Breast Cancer by Regulating PEDF Expression","authors":"洪宏海, 杨卫琴, 唐希才","doi":"10.12677/WJCR.2018.81008","DOIUrl":"https://doi.org/10.12677/WJCR.2018.81008","url":null,"abstract":"Objective: To investigate the molecular mechanism of estradiol E2 to promote the proliferation of breast cancer by regulating the expression PEDF. Methods: Serum PEDF level was detected by ELISA kit and estradiol E2 level was detected by radioimmunoassay; the effect of estradiol on the PEDF regulation was detected by Western blot; the proliferation of breast cancer cell line MCF-7 was detected by MTT assay. Results: The expression of PEDF was down regulated in breast cancer, and negatively correlated with estradiol E2 level. Estradiol E2 can reduce the expression of PEDF and promote the proliferation of breast cancer cell MCF-7. Conclusion: Estradiol E2 can promote the proliferation of breast cancer by regulating the expression of PEDF.","PeriodicalId":22619,"journal":{"name":"The Journal of Cancer Research","volume":"36 1","pages":"49-54"},"PeriodicalIF":0.0,"publicationDate":"2017-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79344139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of DNA Repair Genes Polymorphisms on Incidence and Prognosis of Breast Cancer in an Egyptian Cohort","authors":"Ebtsam R. Zaher, Mahmoud A. Hemida, M. Al-Naggar","doi":"10.12691/JCRT-5-4-2","DOIUrl":"https://doi.org/10.12691/JCRT-5-4-2","url":null,"abstract":"Background: Sporadic breast cancer might be caused by low-penetrance genes, including genes constituting the DNA repair pathways. Defective DNA repair is a common imprint of cancer that promotes the accretion of DNA errors and genomic instability. The clustering of damage in DNA may stimulate breast carcinogenesis. Aims: The goal of the study is to evaluate the role of single nucleotide polymorphisms in DNA repair genes XRCC1 Arg399Gln, XPD Lys751Gln, RAD51 G135C and XRCC3 Thr241Met as genetic indicators of susceptibility to breast cancer and to evaluate their role in treatment outcome. Methodology: The study included 248 females diagnosed with primary breast cancer and 232 normal healthy females. Patients were clinically followed up for 5 years after completing chemotherapy. Genomic DNA was isolated and the four polymorphisms under investigation were assessed by PCR-RFLP technique. Findings: XRCC1 399Gln, XPD 751Gln and XRCC3 241Met alleles were significantly associated with breast cancer risk (OR = 2.63, 2.17 and 3.21; respectively), with carriers having lower disease free survival (DSF). When grouping patients based on the number of affected genotypes they carry, DFS decreased as the number of affected genotypes increased (PaccumConclusion: XRCC1 Arg399Gln, XPD Lys751Gln and XRCC3 Thr241Met polymorphisms may take a significant part in sporadic breast cancer as risk factors and in prognosis, where patients carrying XRCC1 Arg/Arg, XPD Lys/Lys and XRCC3 Thr/Thr genotypes had significantly diminished risk for breast cancer and higher DFS. DFS decreased as the number of affected genotypes increased. But RAD51 5'UTR G135C polymorphism did not associate with either risk or prognosis of breast cancer.","PeriodicalId":22619,"journal":{"name":"The Journal of Cancer Research","volume":"9 1","pages":"113-119"},"PeriodicalIF":0.0,"publicationDate":"2017-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87678268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of cervical human papillomavirus in women attending for cervical cancer screening by visual inspection in Cte d Ivoire","authors":"O. Abdoulaye, Yeo Alain, B. Blavo-KouameE., Koffi Tchibeh, Saraka Nguessan, Oura K Pierre, Faye-Kette Hortense, Dosso Mireille","doi":"10.5897/JCREO2017.0152","DOIUrl":"https://doi.org/10.5897/JCREO2017.0152","url":null,"abstract":"Human papillomaviruses (HPV) cause precancerous lesions and cancers of the cervix. In Cote d'Ivoire, cervical cancer screening program based on visual inspection is the gold standard. This study aimed to detect high risk (HR) HPV DNA on women attending cervical cancer screening program based on visual inspection after application of acid acetic and Lugol. From March to December 2015, cervical samples from women attending cervical screening were tested for some HR to HPV. HPV DNA was amplified using PGMY09 /11 primers which generated 450 base pairs at the L1 region in which the samples harboring HPV DNA were genotyped using the multiplex PCR with HPV 16, 18, 31, 33, 35, 45 and 51 primers. The mean age of this population was 32 years and of about 339 women enrolled on visual inspection, 6.19% were positive. HPV DNA was obtained in 9.73 of the population in which 31 of 33 samples (93.93.%) of HPV DNA+ were genotyped using multiplex PCR testing for HPV 16,18, 31, 33, 35, 45 and 51, of those women with HPV DNA+; 28.57% had a single infection while 71.43% had a multiple infection. HPV genotypes prevalence followed: HPV 16 (30.00%), HPV 18 (25.00%), HPV35 (20.00%), HPV 45 (20.00%), HPV 51 (3.30%) and HPV 33 (1.60%), by using PCR as gold standard while VIA sensitivity and specificity was 16.12 and 95.45%, respectively. HPV prophylactic vaccine would prevent 33.33% of HR HPV infection with 2v, 33.33% with the 4v and 66.66% with the 9v vaccines, respectively. In Cote d'Ivoire screening for cervical cancer with HR HPV testing and triaging for treatment with visual inspection would represent a very efficient prevention of cervical cancer program. \u0000 \u0000 Key words: Human papillomaviruses (HPV), genotypes, acetic acid (IVA), Cote d’Ivoire.","PeriodicalId":22619,"journal":{"name":"The Journal of Cancer Research","volume":"251 1","pages":"7-15"},"PeriodicalIF":0.0,"publicationDate":"2017-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74505995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}